← Back to Clinical Trials
Recruiting NCT05139277

NCT05139277 Evaluation of the CONVIVO System

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05139277
Status Recruiting
Phase
Sponsor Dartmouth-Hitchcock Medical Center
Condition Glioblastoma
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2022-06-28
Primary Completion 2026-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
CONVIVO systemConventional histologic evaluation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2022-06-28 with a primary completion date of 2026-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The primary objective of this study is to evaluate the diagnostic performance of the CONVIVO confocal endomicroscope in discriminating between normal and abnormal tissue in vivo during brain tumor surgery. The interpretation of intraoperative images obtained in situ will be tested against conventional histologic evaluation of targeted biopsies from imaged tissue. The study team hypothesize that there will be a high degree of correlation between images obtained with the CONVIVO system and conventional histologic interpretation.

Eligibility Criteria

Inclusion Criteria: * Adult patients (age\>18) * Adults presenting with suspected intracranial gliomas (including glioblastoma), cerebral metastasis, meningiomas, acoustic neuromas, and pituitary adenomas, who are surgical candidates * Adults able to provide informed consent. Exclusion Criteria: * Pregnancy * Children (age \<18 years) * Fluorescein sodium (FNa) allergy

Contact & Investigator

Central Contact

Linton T Evans, MD

✉ Linton.T.Evans@hitchcock.org

📞 603-650-5026

Principal Investigator

Linton T Evans, MD

PRINCIPAL INVESTIGATOR

Dartmouth-Hitchcock Medical Center

Frequently Asked Questions

Who can join the NCT05139277 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Glioblastoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05139277 currently recruiting?

Yes, NCT05139277 is actively recruiting participants. Contact the research team at Linton.T.Evans@hitchcock.org for enrollment information.

Where is the NCT05139277 trial being conducted?

This trial is being conducted at Lebanon, United States.

Who is sponsoring the NCT05139277 clinical trial?

NCT05139277 is sponsored by Dartmouth-Hitchcock Medical Center. The principal investigator is Linton T Evans, MD at Dartmouth-Hitchcock Medical Center. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology